Adding stabilizing agents to the lipid bilayer or modifying the surface with ligands can help target specific tissues and minimize drug leakage. Manufacturing processes, such as high-pressure ...

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit returns to unite 140+ biopharma thought ...

MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

We used lipid nanoparticles to deliver mRNA and siRNA to human PCa cells to evaluate our technique’s ability to both restore the lost PTEN and silence the overexpressed AR. Our strategy could ...

Vancouver-based Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential for ...